PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) — Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE).
On September 29, 2026, uniQure’s shares declined significantly after the Company reported updated 48-month data for ifezuntirgene inilparvovec, also known as AMT-130, its investigational gene therapy for Huntington’s disease.
On this news, uniQure’s stock price was down more than 35% during intraday trading on September 29, 2026.
uniQure Investors: If you purchased uniQure stock and suffered financial losses
, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or contact us to learn more about the investigation and your potential legal rights.
Learn more:
https://kehoelawfirm.com/uniqure-securities-investigation-qure/
For a free, no-obligation legal evaluation, contact:
Michael Yarnoff, Esq. | (215) 792-6676, Ext. 804 |
[email protected]
|
[email protected]
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C.
is a plaintiff-side class action law firm representing investors, consumers, and employees in securities fraud, corporate misconduct, antitrust, data breach, consumer fraud, employment, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases recovering more than $10 billion for investors.
Class action legal services are provided on a contingency-fee basis, subject to court approval of attorneys’ fees and expenses.
Attorney Advertising
